Peru’s Health Minister, Silvia Pessah, after announcing the first case of price-fixing agreements for the public purchase of medicines in Peru, has now also revealed that three other similar cases have been identified, which have already been notified to the corresponding authority.
Price manipulation was detected in several products, whose prices for the State appear to have risen significantly and without justification. In one example, Pessah details that a surcharge of over 10 times was discovered for a drug when compared with prices in commercial pharmacies.
As a measure, Pessah also announced that the Ministry of Health (MINSA) would stop buying some of the affected medications, launching a new round of contracts to ensure fair prices. Affected medications include gastrointestinal and cardiovascular treatments, and some used in the treatment of Parkinson’s disease. As it is an ongoing investigation, the names of the companies or individuals involved have not been revealed.
Featured News
T-Mobile Faces Class-Action Lawsuit Over Sprint Merger After Appeal Denied
May 16, 2024 by
CPI
Google Faces Backlash Over Introduction of AI-Generated Summaries in Searches
May 16, 2024 by
CPI
CMA Launches Phase 2 Probe into AlphaTheta’s Acquisition of Serato
May 16, 2024 by
CPI
NFL Executive Escapes Testifying in High-Stakes Trial Over Televised Games
May 16, 2024 by
CPI
EU Consumers Lodge Complaint Against Chinese Retailer Temu Over Content Rules Breach
May 16, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI